Interview with Klaus Heumann, Founder and CEO, Biomax Informatics
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
Address: Robert-Koch-Str. 2
D-82152 Planegg
Germany
Tel: +49 (0) 89 895574-0
Web: http://www.biomax.com/home/home.php
Biomax was founded in 1997 with the mission to develop software solutions based on the actual needs of life science organizations.
In pursuit of this goal, Biomax developed a systematic client consultation process that includes evaluation, feedback and optimization. As a result, Biomax has developed software solutions which address both highly specific and general research needs along the discovery-process pipeline. These software tools and content offer a robust foundation for expanding and building new bioinformatics solutions.
Today, life science organizations need access to relevant knowledge at the right time and in the right context to cut costs and enable efficient prioritization of research and production tasks based on well-defined objectives. To meet this need, Biomax provides computational and knowledge solutions which infer and manage the knowledge indispensable for efficient decision making.
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into…
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine. The company, founded by Professor Ugur Sahin in…
PharmaBoardroom recently sat down with Merck’s EVP and Head of Global Healthcare Operations, Teresa Rodó to unpack her important role within the global group and how Merck has pivoted to…
Merck KGaA has moved to continuously expand its manufacturing capacity and capability in recent years with a number of headline-grabbing investments in sites in its home market of Germany and…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital…
Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to…
German giant Merck KGaA has announced a EUR one billion investment into its headquarters in Darmstadt, Germany up until 2025. The aim of Merck’s proposed investment is to secure…
As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this…
The 2006 acquisition of Schering by Bayer is a prime example of the way that big pharma is now approaching growth through acquisition in this extremely competitive and challenging global…
DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example…
Many companies that are focused in the diabetes segment have recognised the need to strengthen their operations in emerging markets, due to the increased prevalence of the disease in countries…
See our Cookie Privacy Policy Here
